Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05705362

Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion

Hypothesis:

Simple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.

A total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Despite advances in stenting techniques and devices, percutaneous coronary intervention (PCI) for bifurcation lesions remains one of the most challenging and complex procedures. Current guidelines recommend 1-stenting with provisional side branch (SB) approach should be an initial treatment strategy for the bifurcation lesions, based on the previous results of several randomized trials. However, the standardization of the provisional strategy is limited. In particular, there is a recommendation on the treatment technique for SB when SB intervention is required, but It has not been decided in which cases SB treatment is necessary, in the latest European Bifurcation Club (EBC) consensus document.16 In previous studies, the criteria for performing SB opening after MV stent intervention in the 1-stenting with provisional SB approach were varied. In the DK-CUSH II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) or CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) trials, SB intervention was performed when the SB diameter stenosis more than 50%, grade B or higher dissection, or blood flow disturbance (TIMI flow 2 or less) after MV stent insertion. On the other hand, in the Nordic trial, the authors applied strict criteria for SB intervention after MV stent insertion (TIMI flow 2 or less only). Furthermore, there have been conflicting results regarding the clinical and angiographic outcomes of the jailed SB opening strategy after the main vessel (MV) stenting, compared with the simple crossover strategy for non-left main bifurcation lesion.

On this background, this trial aims to compare the clinical outcomes between simple crossover and side branch opening strategies in patients with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) Subject must be at least 19 years of age
  • (2) Patients with non-left main bifurcation lesion (SB diameter ≥2.3 mm)
  • (3) Target lesions amenable for 1-stenting with provisional SB approach by operators' decision
  • (4) Angiographically compromised SB (visual SB stenosis ≥50%) after provisional MV stenting

Exclusion criteria

  • (1) Target lesions requiring elective 2-stenting technique by operators' decision (Observation Group 1)*
  • (2) Patients who inevitably require SB intervention after MV stenting, as follows. (Observation Group 2)*
  • Reduced SB TIMI flow (≤2) after MV stenting
  • SB dissection after MV stenting (≥ Type C)
  • (3) Patients without SB compromise after MV stenting (visually SB stenosis <50%) (Observation Group 3)*
  • (4) Cardiogenic shock (Killip class IV) at presentation
  • (5) Patients with significant valvular heart disease or severe left ventricular systolic dysfunction (ejection fraction <35%)
  • (6) Pregnancy or breast feeding
  • (7) Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • (8) Unwillingness or inability to comply with the procedures described in this protocol

Treatment and study plan

Simple Crossover

Procedure

Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.

Side branch opening

Procedure

According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.

Primary outcomes

  1. Target-lesion failure

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    a composite of cardiac death, myocardial infarction, and target-lesion revascularization

Secondary outcomes

  1. All-cause death

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Death from any causes

  2. Cardiac death

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Death from cardiac causes

  3. Myocardial infarction

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    any myocardial infarction

  4. Target-vessel myocardial infarction

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    myocardial infarction in target-vessel

  5. Target-lesion revascularization

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Clinically indicated target-lesion revascularization

  6. Target-vessel revascularization

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Clinically indicated target-vessel revascularization

  7. Any revascularization

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Repeat revascularization procedure

  8. Stent thrombosis

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    definite or probable stent thrombosis by Academic Research Consortium [ARC] definition

  9. Bleeding

    Time frame: up to 2 years of median follow-up (till 1 year after the last patient enrollment)

    Bleeding ARC type 2, 3 or 5 bleeding

  10. Total procedure time

    Time frame: at 1 day

    procedure time

  11. Total amount of contrast use

    Time frame: at 1 day

    used contrast amount

  12. Incidence of contrast induced nephropathy

    Time frame: 72 hours after the index procedure

    defined as an increase in creatinine of ≥0.5mg/dL or ≥25% from baseline within 72 hours after contrast exposure

Study contacts

Contact information is provided by the study sponsor or research team.

Chang-Wook Nam, MD

CONTACT

[email protected]

82-53-258-7019

Ki Hong Choi

CONTACT

[email protected]

82-2-3410-6653

Sponsors and collaborators

Lead sponsor

Keimyung University Dongsan Medical Center

Other

Registry information

Official study title

Randomized Controlled Trial of Simple CROSSsover Versus Side Branch Opening on Clinical Outcomes in Patients With Non-Left Main BIfurcation LeSion (CROSS-COBIS)

Acronym: CROSS-COBIS

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Jan 30, 2023
Registry last updated
Jan 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.